Translations:Telmisartan/24/ja: Difference between revisions

From Azupedia
Jump to navigation Jump to search
Created page with "== さらに読む == * {{cite journal | vauthors = Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C | display-authors = 6 | title = Telmisartan, ramipril, or both in patients at high risk for vascular events | journal = The New England Journal of Medicine | volume = 358 | issue = 15 | pages = 1547–59 | date = April 2008 | pmid = 18378520 | doi = 10.1056/nejmoa0801317 | publisher = Massachusetts Medical Society | hdl = 2437/8..."
 
(No difference)

Latest revision as of 16:09, 28 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Telmisartan)
== Further reading ==
* {{cite journal | vauthors = Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C | display-authors = 6 | title = Telmisartan, ramipril, or both in patients at high risk for vascular events | journal = The New England Journal of Medicine | volume = 358 | issue = 15 | pages = 1547–59 | date = April 2008 | pmid = 18378520 | doi = 10.1056/nejmoa0801317 | publisher = Massachusetts Medical Society | hdl = 2437/81925 | hdl-access = free }}
* {{cite journal | vauthors = Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P | display-authors = 6 | title = Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | journal = Lancet | volume = 372 | issue = 9644 | pages = 1174–83 | date = September 2008 | pmid = 18757085 | doi = 10.1016/S0140-6736(08)61242-8 | s2cid = 5203511 | url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61242-8/abstract | access-date = 26 November 2019 }}

さらに読む

  • Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. (April 2008). "Telmisartan, ramipril, or both in patients at high risk for vascular events". The New England Journal of Medicine. Massachusetts Medical Society. 358 (15): 1547–59. doi:10.1056/nejmoa0801317. hdl:2437/81925. PMID 18378520.
  • Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. (September 2008). "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial". Lancet. 372 (9644): 1174–83. doi:10.1016/S0140-6736(08)61242-8. PMID 18757085. S2CID 5203511. Retrieved 26 November 2019.